Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
Eleonora RiccioMassimo SabbatiniIvana CapuanoAngela Maria PellegrinoLuigi Annicchiarico PetruzzelliAntonio PisaniPublished in: BMC nephrology (2020)
This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.